Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742161 | 0.90 | TSHR (0.47) | TSHRMAPK1PIM3VCAM1MAPT | |
| SCHEMBL405386 | 0.90 | TSHR (0.47) | TSHRMAPK1PIM3VCAM1MAPT | |
| SCHEMBL20494911 | 0.84 | TSHR (0.45) | TSHRMAPK1PIM3ALDH1A1VCAM1 | |
| SCHEMBL30074833 | 0.84 | PTGES (0.49) | MAPT | |
| SCHEMBL28058590 | 0.84 | TDP1 (0.45) | MAPT | |
| SCHEMBL202476 | 0.84 | PTGES (0.49) | MAPT | |
| SCHEMBL2249257 | 0.84 | TSHR (0.45) | TSHRMAPK1PIM3ALDH1A1VCAM1 | |
| SCHEMBL25231084 | 0.81 | PIN1 (0.49) | MAPK1PIM3ALDH1A1MAPTGFER | |
| SCHEMBL3865918 | 0.81 | PIN1 (0.48) | ALDH1A1MAPT | |
| SCHEMBL202663 | 0.80 | POLB (0.51) | TSHRMAPK1ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998972-B2 | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-7998972-B2 | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| EP-1509521-B1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008041088-A2 | N-HYDROXY BENZAMIDES WITH ANTITUMOR ACTIVITY | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2008-04-10 | — | — | WO | disclosed |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-11-03 | — | — | US | disclosed |
| EP-1509521-A2 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | ABL1, PRKCA, PRKCQ | TSHR 3046/4885MAPK1 251/4885PIM3 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.